Prevention of childhood respiratory pidotimod Efficacy of re-infection.doc

 PAGE \* MERGEFORMAT 5 Prevention of childhood respiratory pidotimod Efficacy of re-infection [Keywords:] children with respiratory tract infections, treatment Pediatric respiratory tract infections are common disease in children during the relevant organs of the body is not perfect organizational structure and development, immune dysfunction, respiratory disease caused by recurrent high. To find an effective immunomodulatory treatment, reduce re-infection of respiratory tract, our department since January 2007 to October 2008, the choice of pidotimod (Fu-exposed children to drink oral liquid for prevention of respiratory tract infection, a significant effect, are summarized as follows. 1 Materials and Methods 1.1 Case Selection Selection criteria: hospital pediatric clinic or hospital to cure children with respiratory tract infection in 32 cases (no malnutrition and congenital immune deficiencies and other underlying diseases, age 6 months to 8 years old, 17 males and 15 females an average of 3.6 years. Diseases: Congenital heart disease in 4 cases of pneumonia, pneumonia in 16 cases, 10 cases of recurrent upper respiratory tract infection, asthma with lower respiratory tract infection in 2 cases. 1.2 Experimental Methods and Statistics observed cases within 6 months before and after treatment the number of respiratory tract infection and disease spectrum, check the blood before and after administration of each case, C-reactive protein, immunoglobulin and T cell subsets. Guidance in all cases a reasonable diet, sequential vaccination, to maintain the same living environment, added in the pidotimod (Jiangsu Wuzhong pharmaceutical company, lot number 090103 oral, both with a course of 2 months. Pidotimod dose:gt; 3 years, 1 month 400 mg bid, po, the first 2 months 400 mg qd, po, lt;3 years, 1 month 200 mg bid, po, the first 2 months 200 mg qd, po. 2 Results 2.1 The results shown in Table 1, Table 2. 2.2 All cases of adverse drug reacti